All In Biotech

Drug Trial Radar · NCT07246031

BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation

An Open-Label, Single-Arm, Phase Ⅱb Clinical Study of BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation

Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Oct 29, 2025

Primary completion

Apr 30, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
BioPhoenix Co., Ltd.Industry
Sponsor type
Industry
First posted
Nov 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase IIb open label study evaluates the safety and efficacy of repeat doses of BPC2001 in combination with standard of care treatment for the prevention of acute graft-vs-host-disease (aGvHD) in subjects following Haploidentical Stem Cell Transplantation (Haplo-SCT).

Conditions

  • Graft -Versus-host-disease
  • aGVHD
  • Haploidentical Stem Cell Transplantation
  • cGVHD

Interventions

  • BPC-2001Drug

    Subjects will receive 6 weekly doses of BPC2001, 100 μg/kg via IV administration after completion of Haplo-SCT.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Grades II-IV aGVHDTime frame: Day 100 after the last infusion of stem cell
  2. AE of BPC2001 in addition to the graft-versus-host disease (GvHD) prophylaxis regimenTime frame: 1 year post-transplant
  3. SAE of BPC2001 in addition to the graft-versus-host disease (GvHD) prophylaxis regimenTime frame: 1 year post-transplant
  4. Lab test values of BPC2001 in addition to the graft-versus-host disease (GvHD) prophylaxis regimenTime frame: 1 year post-transplant
  5. Vital sign of BPC2001 in addition to the graft-versus-host disease (GvHD) prophylaxis regimenTime frame: 1 year post-transplant
  6. Graft failure of BPC2001 in addition to the graft-versus-host disease (GvHD) prophylaxis regimenTime frame: 1 year post-transplant

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, China · Recruiting

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.